These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24636978)

  • 1. Chk1 as a new therapeutic target in triple-negative breast cancer.
    Albiges L; Goubar A; Scott V; Vicier C; Lefèbvre C; Alsafadi S; Commo F; Saghatchian M; Lazar V; Dessen P; Delaloge S; André F; Quidville V
    Breast; 2014 Jun; 23(3):250-8. PubMed ID: 24636978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
    Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
    Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint Kinase 1 (CHK1) Inhibition Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Proton Irradiation via Rad51 Downregulation.
    Choi C; Cho WK; Park S; Shin SW; Park W; Kim H; Choi DH
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32294924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
    Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
    Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types.
    Dinkelborg PH; Wang M; Gheorghiu L; Gurski JM; Hong TS; Benes CH; Juric D; Jimenez RB; Borgmann K; Willers H
    Breast Cancer Res Treat; 2019 Apr; 174(3):605-613. PubMed ID: 30607635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
    Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
    Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing Abiraterone Acetate Efficacy in Androgen Receptor-positive Triple-negative Breast Cancer: Chk1 as a Potential Target.
    Grellety T; Callens C; Richard E; Briaux A; Vélasco V; Pulido M; Gonçalves A; Gestraud P; MacGrogan G; Bonnefoi H; Cardinaud B
    Clin Cancer Res; 2019 Jan; 25(2):856-867. PubMed ID: 30352905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIBF1 suppresses the ATR/CHK1 signaling pathway and promotes proliferation and motility of triple-negative breast cancer cells.
    Ro EJ; Ryu SH; Park EY; Ryu JW; Byun SJ; Heo SH; Kim KH; Baek IJ; Son BH; Lee SW
    Breast Cancer Res Treat; 2020 Aug; 182(3):591-600. PubMed ID: 32529408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
    Bryant C; Rawlinson R; Massey AJ
    BMC Cancer; 2014 Aug; 14():570. PubMed ID: 25104095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.
    Maire V; Baldeyron C; Richardson M; Tesson B; Vincent-Salomon A; Gravier E; Marty-Prouvost B; De Koning L; Rigaill G; Dumont A; Gentien D; Barillot E; Roman-Roman S; Depil S; Cruzalegui F; Pierré A; Tucker GC; Dubois T
    PLoS One; 2013; 8(5):e63712. PubMed ID: 23700430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One therapeutic approach for triple-negative breast cancer: Checkpoint kinase 1 inhibitor AZD7762 combination with neoadjuvant carboplatin.
    Zhu H; Rao Z; Yuan S; You J; Hong C; He Q; Yang B; Du C; Cao J
    Eur J Pharmacol; 2021 Oct; 908():174366. PubMed ID: 34314706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer.
    Quintero M; Adamoski D; Reis LMD; Ascenção CFR; Oliveira KRS; Gonçalves KA; Dias MM; Carazzolle MF; Dias SMG
    BMC Cancer; 2017 Nov; 17(1):727. PubMed ID: 29115931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Aurora Kinase A and CHK1 Inhibition Enhances Radiosensitivity of Triple-Negative Breast Cancer Through Induction of Apoptosis and Mitotic Catastrophe Associated With Excessive DNA Damage.
    Li C; Liao J; Wang X; Chen FX; Guo X; Chen X
    Int J Radiat Oncol Biol Phys; 2023 Dec; 117(5):1241-1254. PubMed ID: 37393021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy.
    Zhou ZR; Yang ZZ; Wang SJ; Zhang L; Luo JR; Feng Y; Yu XL; Chen XX; Guo XM
    Acta Pharmacol Sin; 2017 Apr; 38(4):513-523. PubMed ID: 28042876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes.
    Fink LS; Beatty A; Devarajan K; Peri S; Peterson JR
    Mol Cancer Ther; 2015 Jan; 14(1):298-306. PubMed ID: 25344583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SLFN12 Over-expression Sensitizes Triple Negative Breast Cancer Cells to Chemotherapy Drugs and Radiotherapy.
    Raafat Elsayed AA; Al-Marsoummi S; Vomhof-Dekrey EE; Basson MD
    Cancer Genomics Proteomics; 2022; 19(3):328-338. PubMed ID: 35430566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.
    Montero JC; Esparís-Ogando A; Re-Louhau MF; Seoane S; Abad M; Calero R; Ocaña A; Pandiella A
    Oncogene; 2014 Jan; 33(2):148-56. PubMed ID: 23246963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.
    Wang FZ; Fei HR; Cui YJ; Sun YK; Li ZM; Wang XY; Yang XY; Zhang JG; Sun BL
    Apoptosis; 2014 Sep; 19(9):1389-98. PubMed ID: 24928205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets.
    Sofianidi A; Dumbrava EE; Syrigos KN; Nasrazadani A
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.